ArticlePloS one2015
A cost-effectiveness analysis of a program to control rheumatic fever and rheumatic heart disease in Pinar del Rio, Cuba.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.
- Current Situation of Acute Rheumatic Fever and Rheumatic Heart Disease in Latin America and the Caribbean: A Systematic Review.Global heart · 2022Pooled it
- Prevalence and progression of rheumatic heart disease: a global systematic review and meta-analysis of population-based echocardiographic studies.Scientific reports · 2019Pooled it
- Efficacy of an incentive intervention on secondary prophylaxis for young people with rheumatic fever: a multiple baseline study.BMC public health · 2019Trial
- Long-Term Changes and Disparities in the Global Burden of Rheumatic Heart Disease between 1990 and 2021: An Analysis Based on the Global Burden of Disease (GBD) Study.Research in heart yield and translational medicine · 2026Article
- Bridging Knowledge Gaps in Rheumatic Heart Disease Prevention: A Narrative Review of Educational Interventions Across Resource-Limited Settings.Health services insights · 2026Review
- The economic burden of rheumatic heart disease in the Eastern Mediterranean Region.BMJ global health · 2025Article
- Assessing the evidence for antibiotic management of laboratory-confirmedIJID regions · 2025Review
- The economic case for scaling up health research and development: Lessons from the COVID-19 pandemic.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Framework for developing cost-effectiveness analysis threshold: the case of Egypt.The Journal of the Egyptian Public Health Association · 2024Article
- Research priorities for the primordial prevention of acute rheumatic fever and rheumatic heart disease by modifying the social determinants of health.BMJ global health · 2023Review
- Modalities of group A streptococcal prevention and treatment and their economic justification.NPJ vaccines · 2023Article
- Recent Advances in the Rheumatic Fever and Rheumatic Heart Disease Continuum.Pathogens (Basel, Switzerland) · 2022Review
- Health system costs of rheumatic heart disease care in South Africa.BMC public health · 2021Article
- Screening of asymptomatic rheumatic heart disease among refugee/migrant children and youths in Italy.Pediatric rheumatology online journal · 2019Observational
- Rheumatic Fever: A Disease without Color.Arquivos brasileiros de cardiologia · 2019Article
- Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus.Microbiology and immunology · 2018Article
- Rheumatic heart disease: infectious disease origin, chronic care approach.BMC health services research · 2017Review
- The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children.The Pediatric infectious disease journal · 2017Article
- Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations.Current treatment options in cardiovascular medicine · 2017 · on this mapReview
- A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations.PLoS neglected tropical diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundAcute rheumatic fever (ARF) and rheumatic heart disease (RHD) persist in many low- and middle-income countries. To date, the cost-effectiveness of population-based, combined primary and secondary prevention strategies has not been assessed. In the Pinar del Rio province of Cuba, a comprehensive ARF/RHD control program was undertaken over 1986-1996. The present study analyzes the cost-effectiveness of this Cuban program. METHODS AND
findingsWe developed a decision tree model based on the natural history of ARF/RHD, comparing the costs and effectiveness of the 10-year Cuban program to a "do nothing" approach. Our population of interest was the cohort of children aged 5-24 years resident in Pinar del Rio in 1986. We assessed costs and health outcomes over a lifetime horizon, and we took the healthcare system perspective on costs but did not apply a discount rate. We used epidemiologic, clinical, and direct medical cost inputs that were previously collected for publications on the Cuban program. We estimated health gains as disability-adjusted life years (DALYs) averted using standard approaches developed for the Global Burden of Disease studies. Cost-effectiveness acceptability thresholds were defined by one and three times per capita gross domestic product per DALY averted. We also conducted an uncertainty analysis using Monte Carlo simulations and several scenario analyses exploring the impact of alternative assumptions about the program's effects and costs. We found that, compared to doing nothing, the Cuban program averted 5051 DALYs (1844 per 100,000 school-aged children) and saved $7,848,590 (2010 USD) despite a total program cost of $202,890 over 10 years. In the scenario analyses, the program remained cost saving when a lower level of effectiveness and a reduction in averted years of life lost were assumed. In a worst-case scenario including 20-fold higher costs, the program still had a 100% of being cost-effective and an 85% chance of being cost saving.
conclusionsA 10-year program to control ARF/RHD in Pinar del Rio, Cuba dramatically reduced morbidity and premature mortality in children and young adults and was cost saving. The results of our analysis were robust to higher program costs and more conservative assumptions about the program's effectiveness. It is possible that the program's effectiveness resulted from synergies between primary and secondary prevention strategies. The findings of this study have implications for non-communicable disease policymaking in other resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.